Open Orphan has 'firmly established its core pharma services offering'

Open Orphan has 'firmly established its core pharma services offering'
Proactive analyst Emma Ulker talks to Proactive London about Open Orphan (LON:ORPH). 
She says ORPH has firmly established its core pharma services offering, underpinned
by the world-leading quarantine facilities, unique challenge study models and its established clinical trial services. 
ORPH is focusing on converting an extensive and substantial amount of non-Covid-19 related services worth over £100mln. This is in addition to substantial contracts already
signed with the UK Government for COVID-19 vaccine challenge studies.

Related Keywords

United Kingdom ,London ,City Of ,Emma Ulker , ,Proactive London ,Open Orphan ,United Kingdom Government ,Analyst Interview ,Insight ,Research ,Periodic Research ,Premium Research ,In Depth Analysis ,Small Caps ,Harma Biotech ,Open Orphan Plc ,Lon Orph ,Roactiveinvestors ,ஒன்றுபட்டது கிஂக்டம் ,லண்டன் ,நகரம் ஆஃப் ,ப்ரோவாக்டிவ் லண்டன் ,திறந்த ஆர்ஃபந் ,ஒன்றுபட்டது கிஂக்டம் அரசு ,ஆய்வாளர் நேர்காணல் ,